Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 57.63 -0.02 (-0.03%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sanofi-Aventis S.A. ADR < Previous 1 2 ... 6 7 8 9 10 11 12 13 14 ... 30 31 Next > Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid October 09, 2023 Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. Via Investor's Business Daily Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts October 06, 2023 According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX). Via Benzinga What's Going On With Mirati Therapeutics Stock? October 06, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday. Via Benzinga Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories October 04, 2023 Benzinga Via Benzinga Looking Into Sanofi's Recent Short Interest September 18, 2023 Via Benzinga Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. October 04, 2023 The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. Via Investor's Business Daily Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People October 04, 2023 Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and Via Benzinga Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update October 04, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c Via Benzinga Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment October 04, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Why Shares of Kymera Therapeutics Jumped on Tuesday October 03, 2023 The company had a big bounce after hitting a 52-week low the day before. Via The Motley Fool 'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories October 03, 2023 Benzinga Via Benzinga Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine October 03, 2023 Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb Via Benzinga AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug October 03, 2023 AstraZeneca Plc (NASDAQ: AZN) has Via Benzinga Topics Lawsuit Exposures Financial Legal Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant October 02, 2023 Read the latest report on NanoViricides here Via Benzinga Stock Split Watch: Is Regeneron Pharmaceuticals Next? September 30, 2023 If the biotech does split its stock, it will be a first for the company. Via The Motley Fool Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst September 28, 2023 Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. Via Benzinga Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories September 27, 2023 Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate September 27, 2023 The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE Via Benzinga Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant September 26, 2023 Read the latest report on NanoViricides here Via Benzinga Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review September 26, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants September 25, 2023 Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV Via Benzinga Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit September 21, 2023 U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... Via Benzinga Topics Stocks Exposures US Equities Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session September 21, 2023 Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. Via Benzinga Gold Down Over 1%; FedEx Shares Rise On Earnings Beat September 21, 2023 U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... Via Benzinga Topics Stocks Exposures US Equities Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected September 21, 2023 U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... Via Benzinga Topics Stocks Exposures US Equities Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? September 21, 2023 Travere Therapeutics Inc (NASDAQ: TVTX) announced Via Benzinga Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories September 20, 2023 Benzinga Via Benzinga FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray September 20, 2023 The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type... Via Benzinga Exposures Product Safety 3 Stocks to Buy to Ride Europe’s Coming Market Surge September 19, 2023 With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. Via InvestorPlace Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs September 14, 2023 On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics, Via Benzinga Exposures COVID-19 < Previous 1 2 ... 6 7 8 9 10 11 12 13 14 ... 30 31 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.